Most Popular - The FDA has scheduled an advisory committee meeting for Ampligen, a product developed by Hemispherx Biopharma (AMEX:HEB) for the treatment of Chronic Fatigue Syndrome (CFS), … Continue Reading
Read nowMost Popular - Peregrine Pharmaceuticals (NASDAQ:PPHM) could have big trouble after reporting erroneous clinical trial results that took the stock up 13-fold from its lows this year. Lawsuits … Continue Reading
Read nowMost Popular - Questcor Pharmaceuticals (NASDAQ:QCOR) shares are taking another pounding Monday after the company announced in an 8-k that it “became aware of a U.S. government investigation … Continue Reading
Read nowRecap - Questcor Pharmaceuticals imploded. We said shares would rebound after tuning into the company’s conference call and coming out thinking Questcor’s lead product, H.P. Acthar Gel, … Continue Reading
Read nowLong Ideas - Merge Healthcare (NASDAQ:MRGE) fell hard earlier this year when the company announced changes to its business model. In particular, the company moved to offer subscription-based … Continue Reading
Read nowQuick Picks - On the same day that the company released exciting data from a pre-clinical stemcell experiment in rats – sending shares up more than 90% from … Continue Reading
Read nowLong Ideas - Synergy Pharmaceuticals (NASDAQ:SGYP) recently submitted an IND (Investigational New Drug application) for its IBD (inflammatory bowel disease) treatment, SP-333, and is on track to meet … Continue Reading
Read now